Welcome to our dedicated page for Fosun Internatio news (Ticker: FOSUY), a resource for investors and traders seeking the latest updates and insights on Fosun Internatio stock.
News about Fosun International Limited (FOSUY) covers a broad range of topics reflecting its activities as a global innovation-driven consumer group. Company announcements and media releases describe developments across pharmaceuticals and healthcare, cultural tourism and consumption, financial services, and insurance, as well as updates on its innovation and globalization strategy.
Investors and observers can find news on Fosun’s pharmaceutical and healthcare initiatives, including progress in innovative drugs, medical devices, and healthcare services under entities such as Fosun Pharma and Henlius. Releases highlight clinical and regulatory milestones, new therapeutic indications, and the use of artificial intelligence in areas such as drug development decision-making and clinical trial prediction.
Coverage also includes cultural tourism and consumption news, such as performance and expansion of Club Med resorts under Fosun Tourism Group, cultural events, and consumer-focused projects. In financial services and insurance, news items discuss developments at Fosun Insurance Portugal (Fidelidade), asset servicing activities in Europe, and strategic portfolio adjustments, including asset sales and retained businesses.
Another important theme in Fosun-related news is ESG and sustainability. Articles describe its ESG ratings, inclusion in sustainability indices and yearbooks, climate disclosure practices, and social responsibility programs such as the Rural Doctors Program and contributions to global malaria treatment. Governance and award recognitions, including honors from organizations like Corporate Governance Asia, also feature prominently.
For those following FOSUY, this news stream provides insight into how Fosun advances its stated strategy of "Innovation + Globalization", how its core subsidiaries perform, and how it integrates ESG considerations into its operations. Regularly reviewing these updates can help readers understand the group’s evolving business focus and corporate priorities.
On September 16, 2022, Fosun International signed a strategic cooperation agreement with the Pudong New Area, launching key projects including the Intuitive Fosun headquarters. This initiative, backed by over RMB700 million investment, aims to establish a surgical robot ecosystem to enhance local medical innovation in Shanghai. Intuitive Fosun, a joint venture founded in 2017, has already installed nearly 300 da Vinci systems in China. Fosun continues to invest significantly in technology, with RMB4.6 billion allocated in the first half of 2022, marking a 21% increase from the previous year.
Fosun International reported a 17.7% increase in revenue, amounting to RMB82.89 billion for the first half of 2022. The company clarified that its actual debt is RMB100 billion, significantly lower than the market's perception of RMB650 billion. This figure includes liabilities from subsidiaries, not all of which are directly tied to Fosun itself. Morgan Stanley has maintained an "Overweight" rating with a target price of HK$11.4, citing that Fosun is well-positioned to manage its debts and has liquid assets for near-term obligations.
On September 14, 2022, Fosun refuted foreign media claims regarding Chinese regulatory authorities probing banks about their exposure to the company. Fosun confirmed that the China Banking and Insurance Regulatory Commission had not issued any such requests. Gong Ping, CFO, emphasized that recent shareholdings reductions are part of a strategic asset optimization rather than a reaction to market pressures. For the first half of the year, Fosun reported a revenue increase of 17.7% to RMB82.89 billion and a 35.5% rise in enterprise operation profit, with stable cash balances of RMB117.65 billion.
Summary not available.
Fosun International reported strong financial results for the first half of 2022, achieving total revenue of RMB82.89 billion, up 17.7% year-on-year. Net profit attributable to owners reached RMB2.70 billion, while enterprise operation profit rose 35.5% to RMB2.33 billion. Overseas revenue increased by 30.7%, contributing 46.8% of total revenue. The Group invested RMB4.6 billion in technology and innovation, marking a 21% increase. Fosun's diversified segments in health, happiness, wealth, and intelligent manufacturing all reported revenue growth, indicating resilience amid external challenges.
Fosun International and HSBC China renewed a strategic cooperation agreement to enhance global operations, investment capabilities, and financial resources. The agreement, signed by top executives at Fosun's Bund Finance Center in Shanghai, aims to support economic growth and the development of private enterprises. Fosun reported a total revenue of RMB161.3 billion and total assets of RMB806.4 billion in 2021. The collaboration is expected to bolster Fosun's four business segments: Health, Happiness, Wealth, and Intelligent Manufacturing, while continuing efforts in pandemic prevention and economic development.
Fosun participated in the 2nd China International Consumer Products Expo (CICPE) on July 26, showcasing over 15 renowned global brands. The event attracted more than 1,000 companies from 61 countries. Fosun's Lanvin Group reported a remarkable 108% rise in global sales, reaching EUR339 million in 2021, up 52% from 2020. Fosun Tourism Group's business volume is projected to increase by 198% in the first half of 2022, with Club Med achieving a 336% rise. Fosun's innovation investments reached RMB8.9 billion in 2021, revealing its commitment to driving growth across diverse sectors.
Summary not available.
UBS has assigned a 12-month target price of HK$9.1 for Fosun International, representing a 26% increase from its closing price of HK$7.25 on June 30. UBS believes Fosun can manage near-term refinancing risks through reduced investments and increased asset disposals. The company has successfully refinanced its bonds, and UBS notes that non-core investments can cover refinancing needs in the next year. Moreover, S&P Global Ratings maintains a 'BB Stable' credit rating for Fosun, highlighting its strong debt management. Fosun reported a total debt to capital ratio of 53.8% and historically low debt costs.
Fosun has reported a significant recovery across its business sectors following the easing of epidemic restrictions in Shanghai. As of June 29, dine-in services at the Bund Finance Center have resumed, contributing to an economic rebound. Yuyuan's Jewelry & Fashion segment saw sales rise over 100% year-on-year, while Fosun's tourism operations experienced increased visitor flows, particularly in Sanya. Internationally, Club Med bookings surpassed 2019 levels. Additionally, Fosun Pharma achieved collaborations for drug commercialization in China, indicating growth in its health segment.